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ABSTRACT 
Objectives: The proto-oncogene ETS-related gene (ERG) is consistently overexpressed in 
prostate cancer. Alternatively spliced isoforms of ERG have variable biological activities; 
inclusion of exon 11 (72bp) is associated with aggressiveness and progression of disease. 
Exon 10 (81bp) has also been shown to be alternatively spliced. Within this study we assess 
whether total ERG protein, mRNA and ERG splice isoform mRNA expression is altered as 
prostate cancer progresses.  
Methods: Detection of the TMPRSS2:ERG fusion was done using direct methods (RT-PCR 
and FISH) and indirect methods for ERG mRNA and protein expression using qPCR and 
immunohistochemistry, respectively.  A linear equation method was used to quantitatively 
determine relative proportions of ERG variants (ERG72/∆72, ERG81/∆81) for each sample. 
Results: ERG mRNA and protein expression is increased in patients with advanced prostate 
cancer, with a trend for up regulation in advanced versus localised disease, with higher levels 
of ERG expression significantly associated with seminal vesicle invasion (Stage pT3b) and 
biochemical recurrence. Genes involved in cell migration and invasiveness (Matrix 
metalloproteinase 7, osteopontin and septin 9) are increased in prostate cancers that 
overexpress ERG. In addition, there is a clear indication of increased retention of exons 10 
and 11 in prostate cancer.  
Conclusions: We propose that analysis of ERG and the relative proportions of ERG variants 
may be valuable in determining prognosis and development of prostate cancer.  
 
 INTRODUCTION 
The transcription factor ERG (ETS Related Gene) is overexpressed in 60-80% of prostate 
cancer cases [1-3] and is often attributed to a fusion between the promoter of the TMPRSS2 
gene and the coding region of ERG [4,5].  In benign prostate ERG expression levels are low 
and are not regulated by androgens; however in prostate cancer ERG levels are significantly 
higher especially if fused to the TMPRSS2 promoter which is under the control of androgens. 
Expression analysis of prostate cancers reveals a wide array of genes potentially regulated by 
ERG to include genes involved in cell proliferation such as septin 9 (SEPT9) and metastatic 
pathways such as matrix metalloproteinases (e.g. MMP 3/7/9), osteopontin (OPN) and E-
cadherin [3, 7, 8].  
However, the clinical importance of ERG overexpression and the presence of the TMPRSS2-
ERG fusion in prostate cancer is still unclear as there are reports of a positive, negative and 
zero correlation with development and aggressiveness of prostate cancer.[9-11].  
 Added complexity of fusion transcripts arise due to alternative splicing. Wild type ERG 
consists of 17 exons and expresses multiple splice isoforms [12, 13]. A significant finding has 
been that TMPRSS2-ERG and wild-type ERG variants exhibit differing biological properties 
[13, 14]. A common alternative splicing event within the central activation exon domain 
(CAE) of ERG is inclusion/skipping of a 72 bp exon (herein referred to as exon 11).  Recent 
studies in vitro suggest that the inclusion of the 72bp exon (exon 11) results in increased cell 
proliferation and a more oncogenic phenotype [13]. Exon 10 (81bp) can also be alternatively 
spliced [13].  
We hypothesize that the relative proportions of ERG and its variants alter as prostate cancer 
progresses. If so the analysis of ERG expression and its splice variants in routine clinical 
samples of prostate cancer rather than just the genomic fusion, as detected by FISH, may be 
of value in determining the prognosis. 
MATERIALS AND METHODS 
Tissue samples 
This study utilised tissue samples from fifty-three patients diagnosed between 2000-2009 
with clinically localised hormone naïve adenocarcinoma of the prostate (Table 1) (NRES No. 
09/H0102/48). Cases were selected based on the availability of cases for review and large 
enough tumour foci for sampling, excluding any clinically insignificant cases. Whole 
prostatectomy samples were fixed in neutral buffered saline for 24 hours before processing to 
paraffin wax and embedding in Mega Tissue Cassettes (Tissue-Tek®, Netherlands).  For the 
study, areas of benign and invasive prostate carcinoma were identified, cored and re-
embedded in regular sized cassettes (Tissue-Tek®,). In order to validate the use of RT-PCR 
to detect the fusion, a total of 20 of the 53 cases were randomly selected for both FISH 
analysis and RT-PCR. Subsequently, RT-PCR and qPCR for ERG variants was performed on 
53 cases. 
Fluorescent in situ hybridisation (FISH) analysis. 
Tri-colour FISH on paraffin-embedded prostate tumour tissue was performed using a break-
apart assay designed to detect the microdeletion that occurs between TMPRSS2 and ERG at 
21q22 (Kreatech, UK) as previously described [16]. Slides were counterstained using DAPI 
(4',6-diamidino-2-phenylindole), imaged at x100 magnification (Olympus BX41 microscope) 
and analysed using ISIS software. 
 
Immunohistochemistry 
Each of 40 patient samples were stained using two antibodies to ERG (EP111, Dako, UK and 
EPR3864; Epitomics, USA), in addition to double staining with both ERG EP111 and high 
molecular weight cytokeratin (34BE12,  Dako, UK). All immunohistochemistry, to include 
antigen retrieval was performed on a BondMax™ instrument (Leica Microsystems, UK), 
using Bond™ Epitope Retrieval Solution. Nuclear ERG staining was visualised using the 
Bond™ Polymer Refine Detection system, with a diaminobenzidine chromogen. Cytoplasmic 
staining for high molecular weight cytokeratin staining was visualised using the Bond™ 
Polymer Refine Red Detection. Immunohistochemical expression of ERG was assessed as 
described previously, using a four tier grading system in which the intensity of nuclear 
staining is recorded as; negative, weakly positive, moderately positive and strongly positive 
[17]. The specificity of the ERG antibodies was verified by western blot analysis. In addition, 
we compared the staining pattern for both the EP111 clone and the previously validated 
EPR3864 clone [17], both giving identical results on all cases. The EP111 clone was used for 
comparative analysis with the other variables, due to reduced background. Cases with 
invasive prostatic adenocarcinoma showing strong nuclear positivity by both clones served as 
positive controls. In addition, occasional endothelial cells and lymphocytes stained positively 
for ERG and served as internal controls. Omission of the primary antibodies, served as 
negative controls. 
RNA isolation 
For isolation of RNA from FFPE samples the RNeasy FFPE kit (Qiagen) was used as 
specified in the manufacturer’s instructions with the following modifications: Three 5µm 
sections were deparaffinised in Histoclear for five minutes at 56°C followed by 
centrifugation and washing in ethanol. Samples underwent proteinase K digestion at 56°C 
overnight. RNA yields were determined by A260 measurement using a Nanodrop 
spectrophotometer (Thermo Fischer Scientific, USA). Reverse transcription was performed 
using 500ng of RNA and M-MLV Reverse Transcriptase (Promega, UK) as per 
manufacturers specifications. 
RT- PCR analysis 
Primers to detect TMPRSS2:ERG fusion were as designed by Tomlins et al [7]. 
TMPRSS2:ERG forward 5.-TAGGCGCGAGCTAAGCAGGAG-3’ and TMPRSS2:ERG 
reverse 5’-GTAGGCACACTCAAACAACGACTGG-3’. PCR was carried out using GoTaq 
Hot Start Polymerase (Promega) per manufacturers recommendations. 
Quantitative realtime PCR 
Quantitative realtime PCR was performed using 2x Sybr green master mix (Roche, UK) and 
primers at 300 nmol concentration on TaqMan7300 Sequence detection System (Applied 
Biosystems). Primers were designed to span at least one exon boundary using the Primer 
Express 2.0 software (Applied biosystems, UK) and were purchased from Sigma-Genosys 
(Haverhill, UK) using standard qPCR cycling conditions (Table 2). Fold changes in 
expression were calculated by using a standard curve method [18]. Data were normalised to 
the corresponding β-actin value for each sample.  
Quantitative analysis of ERG variants using LEM-PCR 
To assess the relative proportion of ERG splice isoforms the linear equation method (LEM-
PCR) was used, as described previously [19]. In brief, mRNA expression was quantified 
using Sybr Green,ERG primers (Table 2) and two linear equations (benign and cancer) 
generated. These equations were solved and the contributions of ERG+72/81 and ERG∆72/81 
to the total value of ERG calculated. Values were then re-expressed as percentages. 
Statistics  
Data from experiments are presented as mean +/- standard error mean (SEM), with numbers 
of replicates stated in figure legends. Statistical significance between variables was tested 
using,the paired two-tailed student’s t-test,a Kruskal-Wallis test and the Pearson Chi-Squared 
Test. Biochemical recurrence after radical prostatectomy was defined as a PSA value greater 
than or equal to 0.2ng/ml, with a second confirmatory level of PSA of >0.2 ng/ml  (33). 
 
RESULTS 
ERG mRNA expression is increased in TMPRSS2-ERG fusion positive samples. 
We analysed TMPRSS2-ERG gene fusion in cancer samples using both RT-PCR and FISH 
in an initial 20 cases selected at random to determine concordance between the techniques 
(Figure 1). The RT-PCR reaction detected one, two or no TMPRSS2-ERG fusion variants 
(Figure 1A). RT-PCR and FISH results were highly concordant (18/20), with RT-PCR giving  
an additional two cases as TMPRSS2-ERG positive compared with FISH. Using RT-PCR on 
all 53 cases within this study we identified 58% (31/53) of samples to have a TMPRSS2-ERG 
fusion event. ERG mRNA expression determined using real-time PCR was significantly 
increased in TMPRSS2-ERG fusion positive cancer samples compared with fusion negative 
samples, p<0.01(Figure 1C). 
Analysis of ERG mRNA and protein expression in prostate cancer cases  
ERG protein expression by immunohistochemistry correlated with ERG mRNA expression 
(Figure 2A and 2B). ERG staining was exclusively nuclear and homogenous in expression 
and specific to invasive tumour nuclei and the nuclei of PIN. The cells of adjacent normal 
prostate glands remained unstained Figure 2A).. On average cases that had medium or strong 
staining by immunohistochemistry for ERG had significantly higher levels of ERG mRNA 
expression (17.99±5.49), as determined by qPCR, than cases with none or low 
immunohistochemical staining for ERG (4.59±1.94,  p=0.019; Figure 2B). ERG mRNA 
expression was significantly up regulated in both localised (Stage T2, p=0.000416) and 
advanced cancer (Stages T3A, p=0.00397 and T3B, p=0.04120) cases when compared with 
benign prostate tissue (Figure 2C). In addition, ERG was significantly up regulated in Stage 3 
cancer compared to Stage T2 (p=0.009512).  
Quantitative analysis of ERG target gene expression in prostate cancer FFPE samples 
that either have low or high ERG gene expression 
Samples were designated as having high levels of ERG (ERG_high) if they had a 2-fold 
increase in ERG compared with benign tissues. On average the ERG_high subset had a 16-
fold increase in ERG mRNA expression compared with the ERG_low subset, p=0.0022 
(Figure 3A). Increased mRNA expression for  Matrix metalloproteinase 7 (MMP7) p=0.3483 
osteopontin (OPN)p=0,0468 and septin 9 (SEPT9)o=0.00697 mRNA expression was seen in 
prostate tumours with high ERG mRNA expression compared with low ERG mRNA 
expressing tumours (Figure 3B).  
Quantitative analysis of ERG expression is associated with seminal vesicle invasion and 
biochemical recurrence. 
Stage 3 disease was significantly associated with biochemical recurrence (p = 0.008). High 
levels of ERG expression was significantly associated with Stage T3b disease (seminal 
vesicle invasion, p=0.0045) and biochemical recurrence, with 13/28 of the patients with high 
levels of ERG in their tumour having biochemical recurrence, compared to just 3/25 of the 
cases with tumours showing low levels of ERG (p=0.006) (Table 3). 
 Relative ERG CAE splice isoform expression between benign and prostate tumours 
In benign tissue the relative proportions of ERG72/∆72 and ERG81/∆81 were roughly equal 
(Table 4). However, the percentage of total ERG mRNA that was accounted for by ERG∆72 
(exon 11 skipped) and ERG∆81(exon 10 skipped) was significantly decreased in both T3A 
and T3B advanced cancer cases compared with benign tissue and there was a trend for 
decreased ERG∆72 and ERG∆81 in both Stage T3a and T3b advanced cancer cases when 
compared with T2 localised cancer (Figure 4 and Table 4). 
 
DISCUSSION 
For the first time we show that it is possible to reliably detect TMPRSS2-ERG fusion 
isoforms in routinely collected FFPE clinical samples which have been stored at room 
temperature for over 10 years. FISH is the gold standard for the detection of the TMPRSS2-
ERG fusion on FFPE samples. However, there are limitations to the FISH approach for 
TMPRSS2-ERG detection, as unlike RT-PCR, it is unable to discern between particular 
fusion variants of ERG, which was one of the main objectives of this study.  We therefore 
compared FISH and RT-PCR analysis in a random subset of our cohort, in order to validate 
the RT-PCR approach against a known standard. We observed highly consistent results for 
the detection of TMPRSS2-ERG fusion by FISH and RT-PCR. There are a number of 
discrepancies within the literature on the clinical relevance and value of using TMPRSS2-
ERG as a biomarker. We hypothesise that these discordances may be attributable to the 
attention focused on the TMPRSS2-ERG fusion rather than on the downstream signalling 
effects of ERG. For example the TMPRSS2-ERG fusion can result in non-functional ERG 
transcripts as a result of inclusion of premature stop codons [20, 21]. Additionally, if there is 
TMPRSS2-ERG fusion but androgen signalling is absent or disrupted there will be none or 
little ERG expression in prostate cancer cells [22-24]. As such TMPRSS2-ERG fusion status 
may therefore not always reflect the levels of ERG present. Thus instead of detecting a 
TMPRSS2-ERG fusion the accurate measurement of ERG expression may be of more 
prognostic relevance. Here we show that up-regulation of ERG results in increased 
expression of genes involved in cell proliferation (septin 9), and metastases 
(metalloproteinase 7, and osteopontin) (3, 7, 8), and that high levels of ERG expression are 
significantly associated with seminal vesicle invasion and biochemical recurrence. 
Our study also highlights the potential of immunohistochemistry as a high throughput assay 
for detection of overexpression of ERG in clinical cases. Immunohistochemistry has become 
increasingly utilised as a surrogate marker for the TMPRSS2-ERG fusion status. a [17, 25, 
26]. It is important to note that whilst TMPRSS2 is the most common fusion partner for 
ERG, ERG can also be rearranged and fused with the SLC45A3 and NDRG1 genes. These 
alternative fusion partners can account for approximately 5% of ERG overexpressing prostate 
cancers [27-29]. As such using a TMPRSS2-ERG FISH probe in isolation could result in 
missing a number of prostate cancers that would have significantly elevated levels of ERG. 
Like FISH, immunohistochemistry allows for marker expression to be localised in relation to 
tumour morphology. However, in comparison to FISH, it is relatively inexpensive, 
technically less demanding and readily assessed under the light microscope.  
The added complexity of alternative splicing of the ERG transcript may also influence the 
prognostic properties of ERG. Our results suggest for the first time that there is increased 
retention of both the 72 bp and 81 bp exon as prostate cancer progresses. Bioinformatic 
studies have shown that alternative splicing is highly deregulated in cancer and that one 
consequence may be a reduction in exon skipping and an increase in the use of alternative 5’ 
and 3’ splice sites and intron retention [32]. However, as the retention of the 72bp exon in 
ERG increases cell proliferation and invasion in vitro it is highly possible that the changes in 
relative proportions of ERG variants may significantly contribute to the progression of 
prostate cancer. Future studies will focus on addressing the significance of these ERG splice 
variants in larger cohorts and whether these splice variants may predispose an individual to 
advanced prostate cancer. If found to be clinically relevant, the technology described readily 
lends itself to the testing of ERG and its variants on smaller needle biopsies, and the 
possibility of providing guidance to clinicians on the need for radical treatment. 
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TABLE AND FIGURE LEGENDS 
Figure 1. 
A) RT-PCR was performed on cDNA generated from cancerous regions of prostate from 20 
cases using primers directed against exon1 of TMPRSS2 and exon 4 of ERG to detect the 
TMPRSS2-ERG fusion. PCR products were sequenced to confirm the identity of TMPRSS2-
ERG fusion variants. B) Representative image of a fusion positive and a fusion negative case 
obtained using a triple colour breakapart TMPRSS2-ERG FISH probe.  C) Comparison of 
total ERG mRNA expression in TMPRSS2-ERG positive (n=26) and TMPRSS2-ERG 
negative (n=14) FFPE cases as determined by qPCR (**p<0.01). 
Figure 2. 
A) Representative images of immunohistochemistry for ERG, ERG and high molecular 
weight cytokeratin and H & E staining in ERG_low (top row) and ERG_high (bottom) 
invasive prostate cancers as determined previously using qPCR. B) Comparison between 
ERG immunohistochemical staining and average ERG mRNA expression, as determined by 
qPCR, *p=0.019. C) qPCR analysis comparing ERG mRNA expression in benign (n=12) 
versus localised Stage pT2 cancer pT2 (n=21) **p=0.000416, and benign tissue versus Stage 
pT3A (n=19)**$p=0.00397, and benign tissue versus Stage pT3b (n=13) ***p=0.04120 
cancers.  
 Figure 3. 
qPCR analysis of ERG target gene expression in prostate cancers with high and low values of 
ERG mRNA expression. ERG_high was defined as a 2-fold or greater increase in ERG 
compared with benign tissues. A) Total ERG; on average the ERG_high subset (n=24) had a 
16-fold increase in ERG mRNA expression compared with the ERG_low subset (n=16), 
**p=0.0022, B) ERG-high cancers show increased expression of mRNA for the target genes; 
Matrix metalloproteinase 7 (MMP7 (p=0.3483), osteopontin (OPN) *p=0.0468 and septin 
(SEPT9) **p=0.00697.  
Figure 4. 
Relative proportions of ERG variants plus/minus 72bp exon 11of ERG and plus/minus 81bp 
exon 10 of ERG expressed as percentages of the total ERG present in benign (BN, n=12), 
localised (pT2, n=21) and advanced (pT3A, n=19 and pT3B, n=13) prostate cancer samples 
as determined using the LEM-PCR method. 
Table 4. 
Average values ± standard error mean (SEM) of relative amounts of ERG variants 
(plus/minus 72/81 bp exon) expressed as percentages of the total ERG present in benign (BN, 
n=12), localised (pT2, n=21) and advanced (pT3A, n=19 and pT3B, n=13) prostate cancer 
samples as determined using the LEM-PCR method.  
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Table 1. Clinical parameters for patients used in this study 
 
 
 
 
 
 
 
 
 
Variable Localised prostate cancer Advanced prostate cancer 
 
No. of cases 
 
21 
 
32 
 
Median PSA level ± SD, 
ng/mL 
 
5.34 ± 2.25 
 
12.80 ± 5.39 
 
Gleason score cat. No.  
 
 
 
      3+3 = 6 13 8 
      3+4 = 7 
      4+4= 8+ 
6 
0 
22 
4 
 
Pathologic Stage, No.  
  
       pT2 21 0 
       pT3A 
      pT3B 
0 
0 
19 
13 
          
Comment [A1]:  
Comment [A2R1]: Additional cases 
analysed to include  13 cases of T3b 
 
Table 2: PCR primer sequences used. 
 Forward (5’-3’) Reverse (5’-3’) 
β-Actin GCATGGAGTCCTGTGGCATCC
A 
 
ATCCTGTCGGCAATGCCAGGGT
A 
 
Total ERG      
(exon 16) 
CATCTCCTTCCACAGTGCCCA CTGGATTTGCAAGGCGGCTAC 
ERG∆72bp AGAAACACAGATTTACCATAT
GAGC 
ACCGGTCCAGGCTGATCTC 
ERG 72bp 
exon 
CCTGAAGCTACGCAAAGAATT
ACA 
ACCGGTCCAGGCTGATCTC 
ERG 81bp TCTCCACGGTTAATGCATGC GAAAATAAAAGCTGCACCCCCT 
ERG∆81bp TCACATCTCCACTACCTCAGA
GA 
TTGGGAAAATAAAAGCTGCAC 
MMP7 GAACGCTGGACGGATGGT CATACCCAAAGAATGGCCAAGT 
SEPT9 GGAGCGCATCCCCAAGA CGGACGCCTTTCTCCTCAA 
OPN TGGCTAAACCCTGACCCATCT TCATTGGTTTCTTCAGAGGACA
CA 
Table 3. Clinico-pathological parameters for patients designated with either low or high 
ERG mRNA expression. 
 
 
 
 
 
 
Variable ERG_low ERG_high 
 
No. of cases 
 
25 
 
28 
ERG mRNA expression± SD, 1.03 ± 0.10 16.72 ± 5.34 
 
Median PSA level ± SD, 
ng/mL 
 
7.70 ± 1.52 
 
7.82 ± 1.12 
 
Gleason score cat. No.  
 
 
 
      3+3 = 6 11 10 
      3+4 = 7 
      4+4= 8+ 
13 
1 
15 
3 
 
Pathologic Stage, No.  
  
       pT2 12 9 
       pT3A 
      pT3B 
10 
3 
9 
10 
        
Biochemical recurrence 
 
3/25 (12.5%) 
 
13/28 (46%) 
   
  
 
 
  
Table 4. Relative proportions of ERG with/without the 72bp or 81bp exon in clinical prostate 
samples 
 Average ± SEM p-value (ERG72 vs. ERG∆72) 
 ERG72 (%) ERG∆72 (%) BN pT2 pT3A pT3B 
BN 51.71 ± 8.64 48.29 ± 8.09 
0.55 0.0012 0.00009 0.00054 
pT2 72.45 ± 7.51 27.64 ± 7.55 
pT3A 86.47 ± 6.23 13.53 ± 6.24 
pT3B 81.82 ± 3.61 18.18 ± 3.61 
       
 Average ± SEM p-value (ERG81 vs. ERG∆81) 
 ERG81 (%) ERG∆81 (%) BN pT2 pT3A pT3B 
BN 57.52 ± 4.87 42.48 ± 7.12 
0.68 0.008 0.015 0.013 
pT2 76.37 ± 2.53 23.63 ± 2.75 
pT3A 94.55 ± 3.27 5.45 ± 12.87 
pT3B 84.78 ± 6.14 15.22 ± 5.04 
